Jump to: Authorized Access | Attribution | Authorized Requests

Study Description
EPIPARK and HBS2 cohorts were analyzed as part of the International Genetics of Parkinson Disease Progression (IGPP) Consortium. EPIPARK is a population-based cohort to study non-motor symptoms in parkinsonism in the city of Lübeck, Germany led by Drs. Meike Kasten and Christine Klein. HBS2 is a recently enrolled subset of participants in the Harvard Biomarkers Study led by Dr. Clemens Scherzer (www.bwhparkinsoncenter.org/biobank) of 89 participants with a diagnosis of Parkinson Disease (PD). Genotyping with Illumina Infinium Multi-Ethnic Genotyping Arrays (MEGA chip) was performed by Dr. Scherzer, Harvard Medical School and Brigham and Women's Hospital. 179 participants with a diagnosis of PD from EPIPARK and 89 participants with a diagnosis of PD from HBS2 met Q/C criteria were analyzed.
Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

Inclusion criteria for PD cases were age 21 years or older, diagnosis of PD according to UK PD Society Brain Bank criteria or according to movement disorders specialist assessment, and Mini-Mental State Examination scores >21 or next of kin present to provide informed consent.

Exclusion criteria for PD cases were diagnosis of a blood or bleeding disorder, known hematocrit <30%, known active ulcer, or active colitis. Diagnosis of cases was monitored during follow-up to ensure high diagnostic accuracy.

Study History


Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
See articles in PMC citing this study accession
Study Attribution
  • Principal Investigator
    • Clemens R. Scherzer, MD. Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA.
  • Funding Source
    • R01NS115144. National Institute of Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.